195 related articles for article (PubMed ID: 18492024)
41. Octreotide in the outpatient therapy of cirrhotic chylous ascites: a case report.
Berzigotti A; Magalotti D; Cocci C; Angeloni L; Pironi L; Zoli M
Dig Liver Dis; 2006 Feb; 38(2):138-42. PubMed ID: 16389001
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping.
Arts J; Caenepeel P; Bisschops R; Dewulf D; Holvoet L; Piessevaux H; Bourgeois S; Sifrim D; Janssens J; Tack J
Clin Gastroenterol Hepatol; 2009 Apr; 7(4):432-7. PubMed ID: 19264574
[TBL] [Abstract][Full Text] [Related]
43. Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites.
Sharma P; Puri P; Bansal N; Singla V; Kumar A; ShriHari AA; Arora A
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e499-e504. PubMed ID: 34034268
[TBL] [Abstract][Full Text] [Related]
44. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites.
Sàbat M; Guarner C; Soriano G; Bulbena O; Novella MT; Ortiz J; Ricart E; Villanueva C; Rosello J; Rodríguez J; Balanzó J
Dig Dis Sci; 1998 Oct; 43(10):2184-9. PubMed ID: 9790452
[TBL] [Abstract][Full Text] [Related]
45. Midodrine in Liver Cirrhosis With Ascites: A Systematic Review and Meta-Analysis.
Shrestha DB; Budhathoki P; Sedhai YR; Baniya RK; Karki P; Jha P; Mainali G; Acharya R; Sodhi A; Kadaria D
Cureus; 2022 Jul; 14(7):e27483. PubMed ID: 36060403
[TBL] [Abstract][Full Text] [Related]
46. Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and meta-analysis.
Guo TT; Yang Y; Song Y; Ren Y; Liu ZX; Cheng G
J Dig Dis; 2016 Jan; 17(1):11-9. PubMed ID: 26630543
[TBL] [Abstract][Full Text] [Related]
47. Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate.
Hiruy A; Nelson J; Zori A; Morelli G; Cabrera R; Kamel A
Eur J Gastroenterol Hepatol; 2021 Jan; 33(1):102-106. PubMed ID: 32243349
[TBL] [Abstract][Full Text] [Related]
48. The management of hepatorenal syndrome.
Carl DE; Sanyal A
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: a prospective, randomized, single-blind, two-period, crossover, placebo-controlled study.
Lamarre-Cliche M; Souich Pd; Champlain Jd; Larochelle P
Clin Ther; 2008 Sep; 30(9):1629-38. PubMed ID: 18840368
[TBL] [Abstract][Full Text] [Related]
50. Components of the renin-angiotensin-aldosterone system in plasma and ascites in hepatic cirrhosis.
Kuiper JJ; Boomsma F; van Buren H; de Man R; Danser AH; van den Meiracker AH
Eur J Clin Invest; 2008 Dec; 38(12):939-44. PubMed ID: 19021719
[TBL] [Abstract][Full Text] [Related]
51. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.
Mystakidou K; Katsouda E; Tsilika E; Smyrniotis V; Vassiliou I; Tsiatas M; Vlahos L
Anticancer Res; 2006; 26(3B):2325-8. PubMed ID: 16821610
[TBL] [Abstract][Full Text] [Related]
52. Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial.
Ali A; Farid S; Amin M; Kassem M; Al-Garem N
Hepatogastroenterology; 2014 Oct; 61(135):1915-24. PubMed ID: 25713888
[TBL] [Abstract][Full Text] [Related]
53. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome.
Esrailian E; Pantangco ER; Kyulo NL; Hu KQ; Runyon BA
Dig Dis Sci; 2007 Mar; 52(3):742-8. PubMed ID: 17235705
[TBL] [Abstract][Full Text] [Related]
54. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis.
Chen TA; Tsao YC; Chen A; Lo GH; Lin CK; Yu HC; Cheng LC; Hsu PI; Tsai WL
Scand J Gastroenterol; 2009; 44(5):619-25. PubMed ID: 19191184
[TBL] [Abstract][Full Text] [Related]
55. Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine.
Hoeldtke RD; Bryner KD; Hoeldtke ME; Hobbs G
Clin Auton Res; 2006 Dec; 16(6):390-5. PubMed ID: 17036177
[TBL] [Abstract][Full Text] [Related]
56. Model for End-Stage Liver Disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system?
Cuomo O; Perrella A; Arenga G
Transplant Proc; 2008; 40(6):1906-9. PubMed ID: 18675085
[TBL] [Abstract][Full Text] [Related]
57. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
Matulonis UA; Seiden MV; Roche M; Krasner C; Fuller AF; Atkinson T; Kornblith A; Penson R
J Pain Symptom Manage; 2005 Dec; 30(6):563-9. PubMed ID: 16376743
[TBL] [Abstract][Full Text] [Related]
58. Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study.
Maddukuri G; Cai CX; Munigala S; Mohammadi F; Zhang Z
Dig Dis Sci; 2014 Feb; 59(2):471-81. PubMed ID: 24146317
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the effect of midodrine versus octreotide on hemodynamic status in cirrhotic patients with ascites.
Minakari M; Faiiaz L; Rowshandel M; Shavakhi A
J Res Med Sci; 2011 Jan; 16(1):87-93. PubMed ID: 21448389
[TBL] [Abstract][Full Text] [Related]
60. Midodrine reduces new-onset acute kidney injury and hyponatremia in children with cirrhosis and ascites awaiting liver transplantation: Results from an open-label RCT.
Ashritha A; Lal BB; Khanna R; Sood V; Sood AK; Alam S
J Pediatr Gastroenterol Nutr; 2024 Feb; 78(2):350-359. PubMed ID: 38374552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
